Current and future applications of the anti-IgE antibody omalizumab

Cristoforo Incorvaia1, Marina Mauro2, Gian Galeazzo Riario-Sforza1,Franco Frati3, Francesco Tarantini4, Maurizio Caserini41Allergy/Pulmonary rehabilitation, ICP Hospital, Milan, Italy; 2Allergy Unit, Sant&rsquo;Anna Hospital, Como, Italy; 3University Department of Obstetric, Gynaecologic and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cristoforo Incorvaia, Marina Mauro, Gian Galeazzo Riario-Sforza, Franco Frati, Francesco Tarantini, Maurizio Caserini
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b6d7e8c42c774daebd5b7d44aa092c41
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b6d7e8c42c774daebd5b7d44aa092c41
record_format	dspace
spelling	oai:doaj.org-article:b6d7e8c42c774daebd5b7d44aa092c412021-12-02T06:02:20ZCurrent and future applications of the anti-IgE antibody omalizumab1177-54751177-5491https://doaj.org/article/b6d7e8c42c774daebd5b7d44aa092c412008-03-01T00:00:00Zhttp://www.dovepress.com/current-and-future-applications-of-the-anti-ige-antibody-omalizumab-a55https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Cristoforo Incorvaia1, Marina Mauro2, Gian Galeazzo Riario-Sforza1,Franco Frati3, Francesco Tarantini4, Maurizio Caserini41Allergy/Pulmonary rehabilitation, ICP Hospital, Milan, Italy; 2Allergy Unit, Sant&rsquo;Anna Hospital, Como, Italy; 3University Department of Obstetric, Gynaecologic and Pediatric Sciences, Perugia, Italy; 4Respiratory Clinical Research, Novartis Farma S.p.A., Origgio, ItalyAbstract: IgE antibodies are a pivotal factor in pathophysiology of allergic diseases, and the possibility of reducing their level by anti-IgE has long been envisioned. Following several attempts, an effective biologic agent was obtained with the recombinant humanized monoclonal antibody (rhuMAb)-E25, known as omalizumab. A number of controlled clinical trials demonstrated its efficacy and safety in the treatment of severe allergic asthma uncontrolled by standard drug treatment with maximal recommended doses, and treatment with omalizumab is currently included in international guidelines on asthma management. Other studies reported a clear effectiveness also in allergic rhinitis, but the cost of the anti-IgE treatment suggests its use in patients with rhinitis concomitant with asthma. Other indications to be further investigated are skin disorders such as atopic dermatitis and IgE-mediated urticaria, as well as adverse reactions to foods, with a particularly important role in preventing food-induced anaphylaxis. Finally, there are data indicating the usefulness of omalizumab when used in combination with allergen specific immunotherapy, in terms of reducing the adverse reactions to treatment and increasing the clinical efficacy.Keywords: IgE, anti-IgE, omalizumab, allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, allergen immunotherapy Cristoforo IncorvaiaMarina MauroGian Galeazzo Riario-SforzaFranco FratiFrancesco TarantiniMaurizio CaseriniDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 1, Pp 67-73 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Cristoforo Incorvaia Marina Mauro Gian Galeazzo Riario-Sforza Franco Frati Francesco Tarantini Maurizio Caserini Current and future applications of the anti-IgE antibody omalizumab
description	Cristoforo Incorvaia1, Marina Mauro2, Gian Galeazzo Riario-Sforza1,Franco Frati3, Francesco Tarantini4, Maurizio Caserini41Allergy/Pulmonary rehabilitation, ICP Hospital, Milan, Italy; 2Allergy Unit, Sant&rsquo;Anna Hospital, Como, Italy; 3University Department of Obstetric, Gynaecologic and Pediatric Sciences, Perugia, Italy; 4Respiratory Clinical Research, Novartis Farma S.p.A., Origgio, ItalyAbstract: IgE antibodies are a pivotal factor in pathophysiology of allergic diseases, and the possibility of reducing their level by anti-IgE has long been envisioned. Following several attempts, an effective biologic agent was obtained with the recombinant humanized monoclonal antibody (rhuMAb)-E25, known as omalizumab. A number of controlled clinical trials demonstrated its efficacy and safety in the treatment of severe allergic asthma uncontrolled by standard drug treatment with maximal recommended doses, and treatment with omalizumab is currently included in international guidelines on asthma management. Other studies reported a clear effectiveness also in allergic rhinitis, but the cost of the anti-IgE treatment suggests its use in patients with rhinitis concomitant with asthma. Other indications to be further investigated are skin disorders such as atopic dermatitis and IgE-mediated urticaria, as well as adverse reactions to foods, with a particularly important role in preventing food-induced anaphylaxis. Finally, there are data indicating the usefulness of omalizumab when used in combination with allergen specific immunotherapy, in terms of reducing the adverse reactions to treatment and increasing the clinical efficacy.Keywords: IgE, anti-IgE, omalizumab, allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, allergen immunotherapy
format	article
author	Cristoforo Incorvaia Marina Mauro Gian Galeazzo Riario-Sforza Franco Frati Francesco Tarantini Maurizio Caserini
author_facet	Cristoforo Incorvaia Marina Mauro Gian Galeazzo Riario-Sforza Franco Frati Francesco Tarantini Maurizio Caserini
author_sort	Cristoforo Incorvaia
title	Current and future applications of the anti-IgE antibody omalizumab
title_short	Current and future applications of the anti-IgE antibody omalizumab
title_full	Current and future applications of the anti-IgE antibody omalizumab
title_fullStr	Current and future applications of the anti-IgE antibody omalizumab
title_full_unstemmed	Current and future applications of the anti-IgE antibody omalizumab
title_sort	current and future applications of the anti-ige antibody omalizumab
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/b6d7e8c42c774daebd5b7d44aa092c41
work_keys_str_mv	AT cristoforoincorvaia currentandfutureapplicationsoftheantiigeantibodyomalizumab AT marinamauro currentandfutureapplicationsoftheantiigeantibodyomalizumab AT giangaleazzoriariosforza currentandfutureapplicationsoftheantiigeantibodyomalizumab AT francofrati currentandfutureapplicationsoftheantiigeantibodyomalizumab AT francescotarantini currentandfutureapplicationsoftheantiigeantibodyomalizumab AT mauriziocaserini currentandfutureapplicationsoftheantiigeantibodyomalizumab
_version_	1718400131712155648

Current and future applications of the anti-IgE antibody omalizumab

Ejemplares similares